Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Clinical trial NCT06447623 · RECRUITING

Trial details

NCT number: NCT06447623
Sponsor: Fudan University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Breast Cancer HR+/HER2- Breast Cancer

Start date: 2024-02-01
Primary completion: 2027-02-01
Enrollment: 184

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.